article thumbnail

Sandoz to build biologics plant in Slovenia

European Pharmaceutical Review

Full operations is provisionally planned for late 2026. The company also recently announced an additional €50 million investment to expand its European-based antibiotics production network. This brings the total new investment commitment to the network in the past few years to €250 million.

article thumbnail

Sandoz mobilises critical medicine production in Europe

European Pharmaceutical Review

Sandoz] has the only major remaining vertically-integrated production network for penicillins in Europe” Penicillins are the leading category of antibiotics worldwide, Sandoz highlighted. Launch of these new facilities help to ensure sustainable access to quality antibiotics and spearhead development of biosimilars, Sandoz noted.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novo Nordisk $11b acquisition to support manufacturing capacity

European Pharmaceutical Review

Novo Nordisk specified that the transaction is expected to support an incremental increase in the company’s filling capacity from 2026 and onwards. Increasing capacity Acquisition of the three sites will enable the manufacturing capacity to be expanded at scale and speed.

article thumbnail

Sandoz plans new biologics production plant construction in Slovenia

Pharmaceutical Technology

It represents one of the largest-ever global private-sector investments in the country and strengthens the company’s Europe-wide production network. Work on the new biologics production plant is expected to commence this year, and complete operations are scheduled to begin in late 2026.

article thumbnail

Leaders from Boston Children’s Hospital, Google Cloud, MedCity News, Edgilty Inc, and Clarify Health discuss the future of AI in healthcare

Clarify Health

health system realize $150 billion in savings by 2026. Artificial intelligence (AI) has the potential to affect healthcare in profound ways — propelling better data-driven decisions on diagnoses, treatments, and population health management. Reports indicate that AI can help the U.S.

article thumbnail

EU regulators release new workplan for accelerating clinical research

European Pharmaceutical Review

The 2022-2026 workplan of the initiative Accelerating Clinical Trials in the EU ( ACT EU ) has been published by the European Commission (EC), Heads of Medicines Agencies (HMA) and European Medicines Agency (EMA).

Medicine 105
article thumbnail

EMA publishes mid-point regulatory science strategy report

European Pharmaceutical Review

We will seek opportunities to further progress delivery of the Regulatory Science Strategy to 2025, and the broader European medicines agencies network strategy to 2025, as we emerge from a long period of business continuity. A final report on the regulatory science strategy will be published in 2026, once the strategy has been completed.